MARKET

HARP

HARP

Harpoon Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.59
-0.90
-5.15%
Pre Market: 17.50 +0.91 +5.49% 08:00 07/06 EDT
OPEN
17.50
PREV CLOSE
17.49
HIGH
17.50
LOW
16.25
VOLUME
121.41K
TURNOVER
--
52 WEEK HIGH
25.02
52 WEEK LOW
10.27
MARKET CAP
414.72M
P/E (TTM)
-7.3642
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HARP stock price target is 30.89 with a high estimate of 36.00 and a low estimate of 24.00.

EPS

HARP News

More
Hedge Funds Are Warming Up To Harpoon Therapeutics, Inc. (HARP)
Insider Monkey · 15h ago
Harpoon Therapeutics Announces Changes to Board of Directors
GlobeNewswire · 4d ago
Citigroup Maintains Buy on Harpoon Therapeutics, Raises Price Target to $24
Citigroup maintains Harpoon Therapeutics (NASDAQ:HARP) with a Buy and raises the price target from $23 to $24.
Benzinga · 6d ago
Harpoon Therapeutics (HARP) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/24 18:54
Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences
GlobeNewswire · 06/17 12:30
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
GlobeNewswire · 06/11 12:30
71 Biggest Movers From Yesterday
Gainers Cemtrex, Inc. (NASDAQ: CETX) shares climbed 172.4% to close at $2.58 on Monday following earlier press release highlighting release of new thermal body temperature measurement camera, the V1100B-THM-TEMP.
Benzinga · 06/02 08:39
MYOV, NBRV, RWLK and WWR among midday movers
Seeking Alpha - Article · 06/01 16:43

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About HARP

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, the Company is developing a pipeline of T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Its TriTAC product candidate, HPN424, is focused on the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
More

Webull offers kinds of Harpoon Therapeutics Inc stock information, including NASDAQ:HARP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HARP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HARP stock methods without spending real money on the virtual paper trading platform.